Effects of suramin, a polysulfonated naphthylurea compound, on metastatic ability, proliferation, and production of plasminogen activators and plasminogen activator inhibitors were studied using the highly metastatic human renal cell carcinoma cell line, SN12C-PM6. After renal subscapular implantation of tumor cells in nude mice, suramin significantly inhibited metastasis of tumor cells to the lungs and liver. In vitro growth of tumour cells was inhibited by suramin in a dose-dependent manner, at relatively low doses (ID50 = 105 µg/ml). Plasminogen activator inhibitor type 2 (PAI-2) production by tumor cells was enhanced by suramin (100 µg/ml), whereas urokinase-type plasminogen activator (uPA) production was suppressed. Thus, the increase in PAI-2 and the decrease in uPA production correlated with the inhibitory effects on tumour growth and metastasis by suramin. Therefore suramin may be beneficial for the treatment of patients with an early stage of renal cancer with potential risk of metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stein CA, 1993, Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res, 53, 2239–48.
Voogd TE, Vansterkenburg ELM, Wilting J and Jansen LHM, 1993, Recent research on the biological activity of suramin. Pharmacol Rev, 45, 177–203.
Dano K, Andreasen PA, Grondahl-Hansen J, et al. 1985, Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res, 44, 139–256.
Markus G, 1988, The relevance of plasminogen activators to neoplastic growth. Enzyme, 40, 158–72.
Suzumiya J, Hasui Y, Sumiyoshi A, Hashida S and Ishikawa E, 1988, Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. Int J Cancer, 42, 627–32.
Hasui Y, Suzumiya J, Marutsuka K, et al. 1989, Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res, 49, 1067–70.
Marutsuka K, Suzumiya J, Kataoka H, et al. 1991, Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. Inv Metastasis, 11, 181–91.
Hasui Y, Marutsuka K, Suzumiya J, et al. 1992, The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer, 50, 871–3.
Naito S, Walker SM and Fidler U, 1989, In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice. Clin Exp Metastasis, 7, 381–9.
Rago R, Mitchen J, Cheng A-L, Oberley T and Wilding G, 1992, Disruption of cellular energy balance by suramin in intact human prostatic carcinoma, a likely antiproliferative mechanism. Cancer Res, 51, 6629–35.
Rago R, Brazy PC and Wilding G, 1992, Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU 145 prostate carcinoma cells. Cancer Res, 52, 6953–5.
Bradford MM, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248–54.
Taylor CW, Lui R, Fanta P and Salmon SE, 1992, Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst, 84, 489–94.
Chang SY, Yu SS, Sherwood ER, Kozlowski JM and Lee C, 1992, Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol, 147, 1147–50.
Wade TP, Kasid A, Stein CA, et al. 1992, Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in culture. J Surg Res, 53, 195–8.
Sola F, Farao M, Marsiglio A and Grandi M, 1993, Inhibition of lung and liver tumor colonies in mice pretreated with suramin. Inv Metastasis, 13, 163–8.
Klecker RW Jr and Collins JM, 1985, Quantification of suramin by reverse-phase ion-pairing highperformance liquid chromatography. J Lig Chromat, 8, 1685–96.
Constantopoulos G, Rees S, Cragg BG, Barranger JA and Brady RO, 1980, Experimental animal model for mucopolysaccharidosis: suramin-induced glycosamino glycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci USA, 77, 3700–4.
Eisen V and Loveday C, 1973, Effects of suramin on complement, blood clotting, fibrinolysis and kinin production. Br J Pharmacol, 49, 678–87.
Nakajima M, DeChavigny A, Johnson CE, et al. 1991, Suramin: a potent inhibitor of melanoma heparanase and invasion. J Biol Chem, 266, 9661–6.
Zabrenetzky V, Kolm EC and Robberts DD, 1991, Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins. Cancer Res, 50, 5937–42.
Behrendt N, Ronne E and Dane K, 1993, Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem, 269, 5985–9.
Ellis V and Dane K, 1993, Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J, 296, 505–10.
Takano S, Gately S, Neville ME, et al. 1994, Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res, 54, 2654–60.
Marutsuka K, Suzumiya J, Komada N, et al. 1990, Correlation between plasminogen activator production and growth of human tumor cell lines. Proc 49th Jpn Cancer Ass Meet, p. 197.
LaRocca RV, Stein CY, Danesi R, et al. 1991, A pilot study of suramin in the treatment of metastatic renal cell carcinoma. Cancer, 67, 1509–13.
Motzer RJ, Nanus DM, O'Moore P, et al. 1992, Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res, 52, 5775–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marutsuka, K., Hasui, Y., Asada, Y. et al. Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. Clin Exp Metast 13, 116–122 (1995). https://doi.org/10.1007/BF00133616
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00133616